Enterprise Value
40.57M
Cash
157.3M
Avg Qtr Burn
-18.2M
Short % of Float
5.07%
Insider Ownership
0.34%
Institutional Own.
73.75%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IK-175 (AHR Inhibitor) Details Solid tumor/s, Cancer, Bladder cancer, Urothelial carcinoma | Phase 1b Data readout | |
IK-930 (TEAD1) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
IK-007 Details Solid tumor/s, Colorectal cancer , Cancer | Failed Discontinued |